C. Kent Osborne – författare

It has been recognized for many years that cancers originating in the breast and prostate gland are frequently 'endocrine-dependent. ' Traditional thera­ pies included surgical endocrine ablative procedures or pharmacologic hor­ mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biology and mechanisms of action of steroid hormones. In some instances, these new treatments have elimin­ ated or reduced the need for major surgical ablative procedures or for toxic hormone therapy. The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. Thus, an objective review of the current status of these new therapeutic approaches is of interest. In this volume we have attempted to provide an in-depth review of both basic and clinical research involving several new treatment strategies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogues, which can be used effectively to induce 'medical castration. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec­ tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels. Antiestrogen mechanism of action and its clinical implications for the design of innovative treatment approaches is considered in chapters 7 and 8.

Stay on top of the latest knowledge in the field with this must-have resource for all clinicians who treat breast diseases.Expand your knowledge of every aspect of breast diseases as a diverse and distinguished group of internationally-recognized experts summarize the current knowledge, including biology and epidemiology, clinical features, and management. Ideal for any clinician seeing patients with breast disease, especially carcinoma of the breast, This full color 5th Edition of the authoritative text in the field is designed to foster the understanding necessary to provide optimal patient care..FeaturesCovering the latest major clinical trials, along with concise management summaries for each clinical chapter. Illustrations and tables that emphasize breast imaging, microscopic and gross histology, anatomy, and procedural technique enhance visual understanding.Algorithms on problem management in all aspects of breast disease from benign processes to breast carcinoma inform clinical practice.eBook with content updates is included with purchaseNew chapters have been added on pathology of in situ carcinomas, prophylactic contralateral mastectomy, implications of obesity in breast cancer, and an overview of survivorship issuesTo keep perspectives fresh and updated, over one third of the authors are new to this editionNow with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to:Complete content with enhanced navigationA powerful search tool that pulls results from content in the book, your notes, and even the webCross-linked pages, references, and more for easy navigationHighlighting tool for easier reference of key content throughout the textAbility to take and share notes with friends and colleaguesQuick-reference tabbing to save your favorite content for future use

It has been recognized for many years that cancers originating in the breast and prostate gland are frequently 'endocrine-dependent. ' Traditional thera­ pies included surgical endocrine ablative procedures or pharmacologic hor­ mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biology and mechanisms of action of steroid hormones. In some instances, these new treatments have elimin­ ated or reduced the need for major surgical ablative procedures or for toxic hormone therapy. The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. Thus, an objective review of the current status of these new therapeutic approaches is of interest. In this volume we have attempted to provide an in-depth review of both basic and clinical research involving several new treatment strategies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogues, which can be used effectively to induce 'medical castration. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec­ tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels. Antiestrogen mechanism of action and its clinical implications for the design of innovative treatment approaches is considered in chapters 7 and 8.